Official Title

Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy
  • Phase

    Phase 3
  • Study Type

    Interventional
  • Study Participants

    436
The purpose of this study is to evaluate the efficacy and safety of bisphosphonates in long term treatment of osteoporosis.
Is a continued treatment with alendronate for another two years after a preceding therapy with bisphosphonates of at least four years able to reduce the incidence of new osteoporotic fractures in patients at high fracture risk compared to a therapy-free interval?
Study Started
Feb 29
2012
Primary Completion
Mar 31
2013
Study Completion
Mar 31
2013
Results Posted
Jan 17
2019
Last Update
Feb 12
2019

Drug Alendronate

70 mg per week

  • Other names: Fosamax

Drug Placebo

1 pill per week

Alendronate Active Comparator

Placebo Placebo Comparator

Criteria

Inclusion Criteria:

Postmenopausal women or men > 60 years
DXA T-Score at lumbar spine, total hip or femur neck <-2,0 before the start of the bisphosphonate therapy or at baseline or at least one low trauma vertebral fracture grade 2-3 or multiple low trauma vertebral fractures independent of bone mineral densitiy
Pretreatment with bisphosphonates for at least four years
Risk for hip and vertebral fractures min. 30% according to DVO-guideline for osteoporosis 2009
Signed informed consent

Exclusion Criteria:

Other pharmacological treatment of osteoporosis during the last 48 months
Other bone diseases
Malabsorption syndromes
Renal insufficiency with a calculated creatinine clearance < 35 ml/min
Diseases of the esophagus, delayed esophageal clearance
UUnability to realise the intake instructions
Hypocalcemia

Summary

Placebo

Alendronate

All Events

Event Type Organ System Event Term Placebo Alendronate

Number of New Osteoporotic Fractures

Number of new osteoporotic fractures. All fractures which occurred without high impact trauma (i.e. atraumatically, minor accidents and falls from standing height and lower) were regarded as osteoporotic fractures, except for fractures of fingers, face, skull and toes.

Placebo

5.0
osteoporotic fractures

Alendronate

5.0
osteoporotic fractures

Mortality

Number of deaths

Placebo

Alendronate

Combination of New Osteoporotic Fractures and Deaths

Number of participants with a new osteoporotic fracture or death

Placebo

Alendronate

Total

436
Participants

Age, Continuous

74.8
Years (Mean)
Standard Deviation: 7.0

Region of Enrollment

Sex: Female, Male

Overall Study

Placebo

Alendronate